Familial precocious puberty in boys usually presents by age 4 with rapid VIRILIZATION and is also characterized by gonadotropin-independent testosterone secretion, low secretion of LUTEINIZING HORMONE, and advanced SPERMATOGENESIS in the testis. Mutations in the LHCGR gene have been identified. OMIM: 176410
| Excerpt | Reference |
|---|
| "Familial male precocious puberty is a gonadotropin-independent form of precocious puberty that occurs only in males." | ( Albertson, BD; Barnes, KM; Cutler, GB; Diggs, RL; Doppman, JL; Feuillan, PP; Girton, ME; Loriaux, DL; Manasco, PK, 1991) |
| "Central precocious puberty is effectively treated with long-acting LHRH analogs (LHRHas)." | ( Barnes, KM; Cutler, GB; Pescovitz, OH, 1991) |
| "All types of precocious puberty are characterized by rapid growth and advancement of skeletal age, leading to the paradox of the tall child becoming a short adult as a result of premature epiphyseal fusion." | ( Styne, DM; Wheeler, MD, 1990) |
| "In contrast, central precocious puberty is considered a more serious disorder that causes progressive secondary sexual development, accelerated growth and skeletal maturation, early epiphyseal fusion, and short adult stature." | ( Barnes, KM; Cutler, GB; Hench, KD; Loriaux, DL; Pescovitz, OH, 1988) |
| "True precocious puberty is frequently secondary to intrinsic central nervous system pathology, but is rare following external head trauma." | ( Chernausek, SD; Shaul, PW; Towbin, RB, 1985) |
| "Four boys with sexual precocity are described in whom pubertal concentrations of plasma testosterone were associated with premature Leydig and germinal cell maturation without activation of the hypothalamic-pituitary gonadotropin unit." | ( Grumbach, MM; Kaplan, SL; Rosenthal, SM, 1983) |
| "True precocious puberty is reported in a male child with Prader-Labhart-Willi syndrome." | ( Bernasconi, S; Caronna, N; Giovannelli, G; Terzi, C; Vanelli, M; Virdis, R, 1984) |
| "Central precocious puberty is defined as the appearance of morphological and biological changes induced by the early maturation of the hypothalamic-pituitary-gonadal system before eight years of age in girls and ten years of age in boys." | ( Blumberg-Tick, J; Boucekkine, C; Chaussain, JL; Roger, M; Thomas, F, 1994) |
| "Precocious puberty is a frequent and unnatural event in these girls." | ( Benelli, M; Ghizzoni, L; Pezzini, B; Radetti, G; Street, ME; Virdis, R; Volta, C; Zampolli, M, 1998) |
| "Testotoxicosis is a form of male precocious puberty caused by heterogeneous activating mutations in the gene for the lutrophin/choriogonadotrophin receptor (LHR)." | ( Gondos, B; Kosugi, S; Mori, T; Müller, J; Shenker, A, 1998) |
| "Familial male precocious puberty is a form of precocious puberty resulting from an activating mutation of the luteinizing hormone receptor." | ( Leschek, EW; Weissenberger, AA; Zametkin, AJ, 2001) |
| "Central precocious puberty is commonly treated by gonadotropin releasing hormone (GnRH) agonists." | ( Balzer, I; Hegemann, F; Hildebrandt, J; Jarry, H; Roth, C; Witt, A; Wuttke, W, 2004) |
| "Testotoxicosis is a form of gonadotropin-independent (peripheral) precocious puberty in which boys experience early onset and progression of puberty." | ( Norjavaara, E; Reiter, EO, 2005) |
| "Various causes of precocious puberty are now identified." | ( Fujieda, K; Matsuo, K, 2006) |
| "Peripheral precocious puberty is usually the first MAS manifestation in children, characterized by episodes of hypersecretion of estrogens with a consequent reduction in gonadotropin secretion." | ( Altare, F; Andreo, M; Buzi, F; De Luca, F; de Sanctis, C; de Sanctis, L; De Sanctis, V; Einaudi, S; Lala, R; Matarazzo, P; Rigon, F; Viora, E; Wasniewska, M, 2006) |
| "Whether precocious puberty is a clue for chromosome 22q11 deletion syndrome is also discussed." | ( Akçurin, S; Bircan, I; Karagüzel, G; Yakut, S, 2006) |
| "Sexual precocity is a complex character determined by polygenes." | ( Chu, MX; DI, R; Feng, T; Zhang, BY; Zhang, YJ, 2009) |
| "Testotoxicosis is a rare form of precocious puberty caused by a constitutively activating mutation in the luteinizing hormone receptor (LHR) gene." | ( Eyssette-Guerreau, S; Le Merrer, M; Pinto, G; Polak, M; Sultan, A; Sultan, C, 2008) |
| "Precocious puberty is a significant child health problem, especially in girls, because 95% of cases are idiopathic." | ( Dees, WL; Hiney, JK; Srivastava, VK, 2011) |
| "Precocious puberty is a common problem affecting up to 29 per 100,000 girls per year." | ( Fuqua, JS, 2013) |
| "Testotoxicosis is a rare disorder which presents as isosexual peripheral precocious puberty in males." | ( Büyükünal, C; Ceylaner, S; Ercan, O; Evliyaoğlu, O; Özcabı, B; Özcan, R; Tahmiscioğlu Bucak, F; Tüysüz, B, 2015) |
| "Precocious puberty is often a benign central process in girls, but it is rarely idiopathic in boys." | ( Kashimada, K; Kurosawa, K; Matsuda, N; Morio, T; Tsuji-Hosokawa, A, 2017) |
| "Testotoxicosis is an autosomal-dominant, male-limited disorder." | ( Blomberg Jensen, M; Christiansen, P; Frederiksen, H; Grønkær Toft, B; Juel Mortensen, L; Juul, A; Jørgensen, A; Loya, AC; Nielsen, JE; Rajpert-De Meyts, E; Rønholt, AM; Skakkebæk, NE, 2017) |
| "Precocious puberty is pubertal onset before eight years of age in girls and before nine years of age in boys." | ( Emerick, JE; Klein, DA; Sylvester, JE; Vogt, KS, 2017) |
| "Testotoxicosis is a rare cause of peripheral precocious puberty in boys caused by constitutively activating mutations of the LHCG receptor." | ( Arnhold, IJP; Barroso, PS; Bessa, DS; Brito, VN; Cunha-Silva, M; Latronico, AC; Lima, LG; Macedo, DB; Mendonca, BB; Ramos, CO; Segaloff, DL, 2018) |
| "Precocious puberty is characterised by premature appearance of secondary sexual characteristics before the age of 7 years in girls and 9 years in boys." | ( Ahlawat, P; Mishra, S; Rajput, R; Yadav, PK, 2018) |
| "Sexual precocity is a common childhood endocrine disease." | ( Li, S; Shi, Y; Sun, W; Sun, Y; Tian, Z; Wang, Y; Yu, J, 2019) |
| "Precocious puberty is one of the most common endocrine manifestations in MAS." | ( Dong, Z; Lu, W; Wang, J; Wang, W; Wang, X; Xie, Y, 2020) |
| "Precocious puberty is defined when secondary sexual characteristics develop before the age of eight for girls and nine for boys." | ( Chung, LY; Kang, E; Kim, YJ; Lee, KH; Nam, HK; Rhie, YJ, 2020) |
| "Precocious puberty is rare and has a clear female predominance." | ( Argente, J; Latronico, AC; Seraphim, CE; Soriano-Guillén, L; Tena-Sempere, M, 2022) |
| "Central precocious puberty is also caused by some mutations in human KISS1 gene that make the kisspeptin resistant to degradation." | ( Haq, TU; Ilahi, I, 2021) |
| "The prevalence of precocious puberty is increasing." | ( Heidarianpour, A; Razavi, Z; Shokri, E, 2021) |
| Excerpt | Reference |
|---|
| "A presumptive diagnosis of idiopathic precocious puberty was first made and she was treated initially with medroxyprogesterone acetate, and later, with cyproterone acetate." | ( Chapman, C; Hancock, KW; Stitch, SR, 1979) |
| "9 children with precocious puberty were treated over a period of 6 months to 6 3/12 years with Cyproteron acetate or an Ethisterone derivate." | ( Frisch, H; Kemeter, P; Steinert, I, 1977) |
| "8 children with precocious puberty were treated with cyproterone acetate (CPA)." | ( Fehm, HL; Heinze, F; Joos, A; Teller, WM, 1978) |
| "Ten girls with precocious puberty ranging in age from 7 to 10 7/12 years who were treated with oral cyproterone acetate on a long term basis, were subjected to LH-RH tests, prior to and 3 to 16 months after the institution of therapy." | ( Kauli, R; Keret, R; Laron, Z; Prager-Lewin, R, 1977) |
| "10 girls with precocious puberty ranging in age from 7 to 10 7/12 years who were treated with oral cyproterone acetate on a long-term basis, were subjected to LH-RH tests, prior to an 3-16 months after the institution of therapy." | ( Kauli, R; Keret, R; Laron, Z; Prager-Lewin, R, 1977) |
| "In 4 of 5 children with sexual precocity treated with MPA, the LH release evoked by LRF was diminished." | ( Conte, FA; Grumbach, MM; Kaplan, SL; Reiter, EO, 1975) |
| "Also, NPY-treated rats which had precocious puberty showed elevated pituitary and plasma LH levels on the day of VO." | ( Minami, S; Sarkar, DK, 1992) |
| "Twelve children with untreated central precocious puberty were studied." | ( Castro, M; Hiltner, AN; Maciel, LM; Moreira, AC, 1992) |
| "Fourteen girls with idiopathic central precocious puberty were treated with a GnRH analogue." | ( Brauner, R; Malandry, F; Rappaport, R, 1992) |
| "Thirty-four girls with precocious puberty (27 idiopathic, 6 cerebral, 1 McCune-Albright syndrome) were treated with cyproterone acetate (CPA) for 1." | ( Balducci, R; Bozzola, M; Cisternino, M; Lorini, R; Pasquino, AM; Pucarelli, I; Segni, M; Severi, F, 1992) |
| "Central precocious puberty is effectively treated with long-acting LHRH analogs (LHRHas)." | ( Barnes, KM; Cutler, GB; Pescovitz, OH, 1991) |
| "Two girls with precocious puberty (chronological age, 1 and 4 yr; bone age, 3 and 6 yr, respectively) were initially given the diagnosis of idiopathic, central precocious puberty and treated with the LHRH agonist deslorelin (D-Trp6-Pro9-NEt-LHRH) for 5 yr." | ( Cutler, GB; Feuillan, PP; Jones, J; Manasco, PK; Oerter, KE, 1991) |
| "Since 1980 15 girls with sexual precocity who were treated with the superactive GnRH-analogue D-TRP-6-LHRH for 1-5 2/12 years were followed for 1 to 5 6/12 years after discontinuation of therapy." | ( Kauli, R; Kornreich, L; Laron, Z, 1990) |
| "Fourteen patients with precocious puberty were treated for 1-3 years with 900-1800 micrograms/day of intranasal (i." | ( Chan, FL; Cheung, PT; Low, LC; Wang, C, 1989) |
| "Two boys and one girl with idiopathic precocious puberty were treated with medroxyprogesterone acetate (MPA) for 2 years and 2 months to 9 years and 5 months, and its efficiency was evaluated." | ( Kumamoto, Y; Maruta, H; Nanbu, A; Takagi, Y, 1989) |
| "We have studied four girls with central precocious puberty treated with cyproterone acetate for a mean of 3." | ( Adams, J; Brook, CG; Jeffcoate, SL; Pringle, PJ; Stanhope, R, 1985) |
| "In 29 children with central precocious puberty, gonadarche was suppressed with LHRHa administration for 1-4 yr." | ( Beardsworth, DE; Bode, HH; Boepple, PA; Crawford, JD; Crigler, JF; Crowley, WF; Kushner, DC; Mansfield, MJ; Wierman, ME, 1986) |
| "Clinical and biochemical evidence of central precocious puberty was present in one boy at the time of diagnosis at age 7 and developed under hydrocortisone substitution therapy in the two other patients." | ( Drop, SL; Ladée-Levy, JV; Pouw, IS; Slijper, FM, 1986) |
| "Forty-four patients (42 f, 2 m) with precocious puberty (31 idiopathic, 1 familial, 7 cerebral, 5 McCune-Albright) were treated with cyproterone acetate for periods of 1-8." | ( Bierich, JR; Butenandt, O; Heinze, E; Homoki, J; Kiraly, E; Knorr, D; Moeller, H; Ranke, MB; Sorgo, W; Teller, WM, 1987) |
| "Treatment of precocious puberty of central origin is aimed at controlling the development of sexual characteristics and improving final height." | ( Chaussain, JL; Couprie, C; Job, JC; Lacaille, F; Simon, D, 1988) |
| "Forty girls with central precocious puberty (CPP) were studied before and during 1-3 yr of luteinizing hormone-releasing factor (LHRH) agonist (LHRHa) administration to examine the impact of gonadal steroid secretion and its suppression on skeletal growth and maturation." | ( Blizzard, RM; Boepple, PA; Crawford, JD; Crigler, JF; Crowley, WF; Kushner, DC; Link, K; Mansfield, MJ, 1988) |
| "Thirteen young girls with idiopathic precocious puberty were treated with LHRH analogue under a well-established protocol." | ( Crowley, WF; Hall, DA; McCarthy, KA; Simeone, JF; Wierman, ME, 1986) |
| "Before treatment 23 of 33 patients with central precocious puberty presented an increased size of the uterus." | ( Brauner, R; Hauschild, MC; Pariente, D; Rappaport, R; Thibaud, E, 1986) |
| "Six of 18 children had organic precocious puberty, but their responses to therapy did not show any difference." | ( Brauner, R; Rappaport, R, 1987) |
| "In two girls with precocious puberty treated during 12 to 15 months with intranasal administration of HOE 766, urinary excretion of HOE 766-like material was shown to correlate well with the degree of inhibition of plasma 17 beta-E2 and of plasma LH and FSH responses to a GnRH challenge." | ( Aubert, ML; Reznik, Y; Sizonenko, PC; Winiger, BP, 1987) |
| "In 12 patients (11 girls, 1 boy) with central precocious puberty and 4 patients (3 girls, 1 boy) with idiopathic short stature treated for 1 year with a GnRH superagonist, buserelin (0." | ( Bourguignon, JP; Craen, M; Delire, M; Du Caju, M; Heinrichs, C; Lambrechts, L; Malvaux, P; Van Vliet, G; Vanderschueren-Lodeweyckx, M; Vandeweghe, M, 1987) |
| "One boy and 13 girls with central precocious puberty were treated for 1 year using Buserelin, a GnRH analogue, given intranasally (0." | ( Bourguignon, JP; Craen, M; Du Caju, MV; Ernould, C; Malvaux, P; Van Vliet, G; Vanderschueren-Lodeweyckx, M; Vandeweghe, M, 1987) |
| "Eight girls with central precocious puberty were treated with the long-acting gonadotropin releasing hormone analogue leuprolide acetate (Lupron) for a period of six to 18 months." | ( Kappy, MS; Perelman, A; Stuart, T, 1988) |
| "In children with untreated central precocious puberty, the mean serum BGP concentration was significantly higher than in age-matched normal children [mean, 61." | ( Christiansen, C; Giwercman, A; Hartwell, D; Johansen, JS; Nielsen, CT; Price, PA; Skakkebaek, NE, 1988) |
| "We have treated 14 girls with central precocious puberty for a mean period of 2." | ( Brook, CG; Pringle, PJ; Stanhope, R, 1988) |
| "Eight girls and one boy with precocious puberty were treated with intranasal (D-Ser6)-LHRH (buserelin) for 0." | ( Adams, J; Brook, CG; Stanhope, R, 1985) |
| "A 7 year old girl with precocious puberty was treated with buserelin, a long acting analogue of gonadotrophin releasing hormone." | ( McNinch, AW; Savage, DC; Ward, I; Ward, PS, 1985) |
| "Seven children with central precocious puberty and either neurofibromatosis and/or optic gliomas were referred to the National Institutes of Health, Bethesda, Md, for evaluation and treatment with the long-acting luteinizing hormone releasing hormone analogue (LHRHa) D-Trp6-Pro9-NEt-LHRH." | ( Comite, F; Cutler, GB; Hench, K; Laue, L; Loriaux, DL; Pescovitz, OH, 1985) |
| "6 girls and 2 boys with isosexual precocious puberty were treated with 200 mg of medroxyprogesterone acetate (MPA) and studied to determine the drug's effect on plasma growth hormone response to insulin-induced hypoglycemia." | ( Costin, G; Frasier, SD; Kaplan, S, 1969) |
| "A 6-year-old girl with central (true) precocious puberty was successfully treated with a combination of the luteinising hormone releasing hormone analogue (D-Trp6)-LH-RH and cyproterone acetate." | ( Comaru-Schally, AM; Kauli, R; Laron, Z; Schally, AV; Zeev, ZB, 1981) |
| "Six girls and one boy with precocious puberty were treated with a superactive LHRH analogue (D-TRP6-LHRH) for periods ranging from 1 year to 2 years and 3 months." | ( Ben-Zeev, Z; Kaufman, H; Kauli, R; Laron, Z; Lewin, RP; Pertzelan, A; Schally, AM; Schally, AV, 1984) |
| "Seven children with precocious puberty were treated with cyproterone acetate and their adrenal function studied." | ( Savage, DC; Swift, PG, 1981) |
| "Twenty-four girls with sexual precocity who had been treated with cyproterone acetate were followed for periods from 1 to 8 1/2 years after the discontinuation of therapy." | ( Kauli, R; Laron, Z, 1980) |
| "We treated five girls with idiopathic precocious puberty (ages two to eight) for eight weeks with daily subcutaneous injections of LHRHa." | ( Comite, F; Crowley, WF; Cutler, GB; Loriaux, DL; Rivier, J; Vale, WW, 1981) |
| "A two year girl with idiopathic true precocious puberty was treated with a long-acting LHRH agonist, D-Trp6-Pro9-NEt-LHRH (LHRHa)." | ( Comite, F; Crowley, WF; Cutler, GB; Loriaux, DL; Rivier, J; Vale, W, 1981) |
| "In a group of 8 untreated girls with precocious puberty, adult height was 149." | ( Bergadá, C; Boulgourdjian, E; Escobar, ME; Heinrich, JJ; Martinez, A, 1995) |
| "When histrelin is administered to treat central precocious puberty, the rate of secondary sexual maturation is slowed and in some cases there is a reversal of maturation which occurs before initiation of treatment." | ( Barradell, LB; McTavish, D, 1993) |
| "Modern treatment of central precocious puberty (CPP) by agonist analogues of gonadoliberin (aGnRH) block the development of secondary sex characteristics, it delays bone maturation and improves the prospects of reaching optimal height." | ( Kolousková, S; Lebl, J; Snajderová, M; Zemková, D, 1995) |
| "Forty-one girls with central precocious puberty were treated for 28 months (range, 12 to 60 months); 25 of them discontinued therapy at a mean chronological age of 10." | ( Balsamo, A; Bovicelli, L; Brondelli, L; Cacciari, E; Cassio, A; Cicognani, A; Colli, C; Mandini, M; Pirazzoli, P; Tani, G, 1994) |
| "In conclusion, some girls with true precocious puberty and poor adult height prediction who are treated with GnRH analog achieve an adult height more comparable to their target height." | ( Adan, L; Brauner, R; Malandry, F; Zantleifer, D, 1994) |
| "A boy with organically conditioned central precocious puberty and growth hormone deficiency (congenital cyst in the area of the third ventricle) is treated concurrently with an analog of gonadoliberine D-Trp-6-LHRH (Triptorelin) and growth hormone." | ( Kolousková, S; Lebl, J; Pechová, M; Snajderová, M; Zemková, D, 1994) |
| "A group of five girls with central precocious puberty (CPP) (four girls with idiopathic CPP and one girl with organically conditioned CPP) were treated for a mean period of 17 months (12-20 months) with an agonist of gonadoliberine (aGnRH) D-Trp-6-LHRH(Triptorelin), 60-100 micrograms/kg by the i." | ( Kolousková, S; Lebl, J; Pechová, M; Snajderová, M; Zemková, D; Zounarová, M, 1994) |
| "We studied six girls with central idiopathic sexual precocity without any prior gonadal suppression therapy." | ( Kobayashi, Y; Minagawa, M; Murata, A; Niimi, H; Ohnishi, H; Wataki, K; Yasuda, T, 1994) |
| "We conclude that in girls with precocious puberty the activation of gonadal steroid secretion induces an increase in bone mineralization and that oestrogen deprivation by GnRH-a treatment caused a significant decrease in BMD." | ( Baroncelli, GI; Battini, R; Bertelloni, S; Franchi, G; Saggese, G, 1993) |
| "Children with documented central precocious puberty were treated with Lupron Depot for 1." | ( Clemons, RD; Hoekstra, FT; Kappy, MS; Perelman, AH; Stuart, TE, 1993) |
| "Treatment of central precocious puberty in children using Lupron Depot is safe and efficacious." | ( Clemons, RD; Hoekstra, FT; Kappy, MS; Perelman, AH; Stuart, TE, 1993) |
| "Four girls with true precocious puberty and five postmenopausal women were administered GnRH-agonist (3." | ( Ferrari, E; Gandolfi, A; Genazzani, AD; Genazzani, AR; Massolo, F; Petraglia, F, 1996) |
| "Five boys with central precocious puberty (CPP) were studied before and after 12 months of GnRH agonist treatment." | ( Juul, A; Müller, J; Skakkebaek, NE, 1997) |
| "The observation of precocious puberty in an infant with hyperglycinemia followed by pubertal regression during GABA agonist therapy and the in vitro findings in hypothalamic explants suggest that stimulatory inputs mediated through NMDA receptors and inhibitory inputs through GABA receptors are involved in the initiation of puberty." | ( Bourguignon, JP; de Zegher, F; Gerard, A; Jaeken, J, 1997) |
| "We found no evidence that girls with precocious puberty treated with long-acting gonadotropin-releasing hormone analogues have enlarged polycystic ovaries develop." | ( Brocks, V; Holm, K; Jensen, AM; Laursen, EM; Müller, J, 1998) |
| "To evaluate the effect of central precocious puberty (CPP) and its treatment with gonadotropin-releasing hormone (GnRH) analogues on final height and peak bone mass (PBM), we measured lumbar bone mineral density (BMD) in 23 girls at final height." | ( Baroncelli, GI; Bertelloni, S; Perri, G; Saggese, G; Sorrentino, MC, 1998) |
| "Although treatment of girls with precocious puberty should ideally restore estradiol levels to the normal prepubertal range, treatment effectiveness has usually been monitored by gonadotropin levels because estradiol RIAs have lacked sufficient sensitivity to monitor treatment effectiveness." | ( Barnes, KM; Baron, J; Cutler, GB; Klein, KO; Pescovitz, OH, 1998) |
| "Zoladex LA was effective in controlling precocious puberty in girls when given at intervals of 9-12 weeks and it is recommended that an initial assessment is made eight weeks after beginning treatment." | ( Donaldson, MD; Hollman, AS; McNeill, E; Paterson, WF; Reid, S, 1998) |
| "The impact of treatment of central precocious puberty (CPP) with GnRH agonists on final statural height (FH) remains controversial, and guidelines on the optimal time point for interruption of these treatments have not been established." | ( Blumberg, J; Carel, JC; Chaussain, JL; Ispas, S; Lahlou, N; Roger, M; Tondu, F, 1999) |
| "Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr." | ( Antoniazzi, F; Bertoldo, F; Gasperi, E; Lauriola, S; Sirpresi, S; Tatò, L; Zamboni, G, 1999) |
| "A considerable number of patients with central precocious puberty (CPP) treated with depot GnRH agonists have reached final height (FH)." | ( Heger, S; Partsch, CJ; Sippell, WG, 1999) |
| "The impact of treatment of central precocious puberty (CPP) with gonadotropin-releasing hormone agonists (GnRHa) on final height remains controversial." | ( Di Maio, S; Gasparini, N; Micillo, M; Officioso, A; Perna, E; Pisaturo, L; Salerno, M, 2000) |
| "Although it rarely progresses to central precocious puberty the differential diagnostics is essential, as the latter pathology should be treated as early as possible." | ( Januszek-Trzciakowska, A; Lewin-Kowalik, J; Małecka-Tendera, E, 2000) |
| "In girls with central precocious puberty (CPP) the hypothalamic-pituitary-gonadal axis is prematurely activated, if the girl is thereafter treated with GnRH agonists both gonadotropins and estradiol levels become suppressed." | ( Andersson, AM; Müller, J; Sehested, A; Skakkebaek, NE, 2000) |
| "Ten Thai girls with idiopathic central precocious puberty (ICPP) were treated with gonadotrophin releasing hormone (GnRH) analog for a mean period of 1." | ( Aroonparkmongkol, S; Srivuthana, S; Trinavarat, P; Wacharasindhu, S, 2001) |
| "The final height achieved in the 35 (11 central precocious puberty, 24 early puberty) untreated boys was within the range of their respective target height." | ( Kauli, R; Lazar, L; Pertzelan, A; Phillip, M; Weintrob, N, 2001) |
| "Treatment of girls with idiopathic central precocious puberty with GnRH analogues produced a mean height increase of 3." | ( Adan, L; Brauner, R; Chemaitilly, W; Trivin, C, 2002) |
| "Treatment led to regression of precocious puberty and reversal of secondary sexual characteristics." | ( Bajpai, A; Gupta, AK; Kabra, M; Menon, PS; Sharma, J, 2002) |
| "Tamoxifen treatment of precocious puberty in MAS results in a reduction of vaginal bleeding and significant improvements in growth velocity and rate of skeletal maturation." | ( Eugster, EA; Jou, HC; Pescovitz, OH; Plourde, P; Reiter, EO; Rubin, SD, 2003) |
| "Out of 35 girls with idiopathic central precocious puberty (CPP) treated with gonadotropin-releasing hormone agonist (GnRHa) (depot-triptorelin) at a dose of 100 microg/kg every 21 days i." | ( Arcadi, E; Ortore, M; Pasquino, AM; Pucarelli, I; Segni, M, 2003) |
| "Central precocious puberty is commonly treated by gonadotropin releasing hormone (GnRH) agonists." | ( Balzer, I; Hegemann, F; Hildebrandt, J; Jarry, H; Roth, C; Witt, A; Wuttke, W, 2004) |
| "The seven girls with evidence of central precocious puberty had no slowing in the progression of their puberty during the combined fadrozole and GnRH analog treatment." | ( Calis, K; Cutler, GB; Feuillan, PP; Jones, J; Nunez, SB, 2003) |
| "In children with precocious puberty (PP), treatment with GnRH analogs (GnRHa) often decreases height velocity below normal." | ( Barnes, KM; Baron, J; Cutler, GB; Flor, A; Weise, M, 2004) |
| "To distinguish which children with precocious puberty (PP) and early puberty (EP) should be treated and which followed without therapy." | ( Jakubowicz, S; Lanes, R; Soros, A, 2004) |
| "Treatment of precocious puberty with GnRH analogs (GnRHa), by reducing sex steroid levels, leads to a situation of hypoestrogenism that may theoretically have a detrimental effect on bone mass during pubertal development." | ( Antoniazzi, F; Bertoldo, F; Lauriola, S; Tatò, L; Zamboni, G, 2004) |
| "Therefore to treat precocious puberty it may not only be necessary to prevent premature changes in their body but also to give them enough time to face up to their emotional and psychological problems and to become competent adolescents." | ( Capalbo, D; Esposito, V; Ferri, P; Muzzica, S; Officioso, A; Salerno, M, 2004) |
| "Gonadotrophin independent precocious puberty occurred between ages 5-7 years but was slowly progressive, requiring no treatment." | ( Zacharin, M, 2005) |
| "Central precocious puberty (CPP) is treated with GnRH analogues to stabilize secondary sexual characteristics and to prevent loss of final height (FH) due to accelerated bone maturation." | ( Heinrichs, C; Massa, G; Messaaoui, A; Tenoutasse, S, 2005) |
| "The impact of untreated precocious puberty on growth and adult stature is discussed, and the actions of estrogen in the human skeleton are summarized." | ( Eugster, EA, 2004) |
| "The true precocious puberty model by neonatal administration of Danazol in female rats showed augmented expression of hypothalamic GnRH; the Nourishing "Yin"-Removing "Fire" Chinese Herb Mixture down-regulated the increased GnRH expression, and significantly delayed the sexual development of the precocious puberty rat." | ( Cai, D; Chen, B; Sun, Y; Tian, Z; Zhao, H, 2005) |
| "Standard treatment of central precocious puberty (CPP) consists of intramuscular or subcutaneous administration of a gonadotropin-releasing hormone (GnRH) agonist (GnRHa) at 3- to 4-week intervals." | ( Chertin, B; Farkas, A; Gelber, H; Gillis, D; Hirsch, HJ; Lindenberg, T; Spitz, IM; Strich, D, 2005) |
| "Treatment of precocious puberty (PP) in MAS should be considered in patients with poor predicted adult height (PAH)." | ( Likitmaskul, S; Osuwanaratana, P; Santiprabhob, J; Sawathiparnich, P, 2006) |
| "In treatment of idiopathic central precocious puberty, GnRH analogues (GnRHa) have been accepted as the treatment of choice." | ( Jonsson, B; Lönnerholm, T; Proos, LA; Tuvemo, T, 2006) |
| "GnRH analog (GnRHa) therapy for central precocious puberty (CPP) typically involves im injections." | ( Clarke, W; Eugster, EA; Flood, L; Gray, W; Kletter, GB; Lee, PA; Neely, EK; Reiter, EO; Saenger, P; Shulman, D; Silverman, L; Tierney, D, 2007) |
| "Children with central precocious puberty (CPP) treated with Z (n = 34) or ZLA (n = 28) were studied retrospectively." | ( Clayton, PE; Cusick, C; Hall, CM; Isaac, H; Meyer, S; Patel, L; Price, DA, 2007) |
| "Girls with sexual precocity diagnosed after the age of 6 yr exhibit earlier epiphyseal fusion with diminished posttreatment height gain and compromised FHt." | ( Lazar, L; Padoa, A; Phillip, M, 2007) |
| "To evaluate the long-term treatment of testotoxicosis with cyproterone acetate or ketoconazole." | ( Almeida, MQ; Antonini, SR; Arnhold, IJ; Brito, VN; de Castro, M; Guerra-Junior, G; Latronico, AC; Lins, TS; Mendonca, BB, 2008) |
| "Girls with central precocious puberty (CPP) are treated with gonadotropin releasing hormone (GnRH) analogues to suppress puberty." | ( Klein, KO; Kunz, GJ; Sherman, TI, 2007) |
| "Treatment of central precocious puberty continues to be a very active area of clinical investigation, but there are still unresolved questions that future studies will need to address." | ( Kaplowitz, PB, 2009) |
| "In children with central precocious puberty (CPP), gonadotropin-releasing hormone (GnRH) analogue treatment has been associated with an increase in body mass index (BMI)." | ( Baroncelli, GI; Bertelloni, S; Chiocca, E; Dati, E; Erba, P; Mora, S; Parrini, D, 2009) |
| "Forty children with precocious puberty treated with either goserelin or leuprolide (33 females, mean age 7." | ( Cutfield, WS; Gunn, AJ; Hofman, PL; Jefferies, C; Mouat, F, 2009) |
| "Central precocious puberty (CPP) causes early epiphyseal maturation, and early initiation of treatment improves final height." | ( de Vries, L; Gat-Yablonski, G; Phillip, M; Shtaif, B, 2009) |
| "We report a case of precocious puberty in a 10-month-old male secondary to transfer of topical testosterone from his father, who was treated for primary hypogonadism." | ( Cavender, RK; Fairall, M, 2011) |
| "Treatment of testotoxicosis with bicalutamide plus anastrozole resulted in slower growth rate." | ( Amrhein, J; Armstrong, J; De Luca, F; Kulshreshtha, B; Mauras, N; McCormick, K; Melezinkova, H; O'Brien, S; Reiter, EO, 2010) |
| "Central precocious puberty after precocious pseudopuberty may be more common than expected and should be considered in children with persistent or recurrent symptoms after initial treatment of precocious pseudopuberty." | ( Hartmann, MF; Lignitz, S; Partsch, CJ; Pohlenz, J; Wudy, SA, 2011) |
| "Treatment of central precocious puberty (CPP) is the administration of GnRH analogs." | ( Amirhakimi, G; Karamifar, H; Karamizadeh, Z; Saki, F; Tabebordbar, M, 2013) |
| "Central precocious puberty due to HH can be successfully treated with resection." | ( Gong, J; Jia, G; Li, CD; Li, JF; Luo, SQ; Ma, ZY; Zhang, YQ, 2013) |
| "Central precocious puberty (CPP), treated or untreated, may have implications in adulthood." | ( de Vries, L; Lazar, L; Lebenthal, Y; Meyerovitch, J; Phillip, M, 2014) |
| "Of the girls, 30 were treated for central precocious puberty (CPP), 26 had menarche at an average of 12." | ( Eugster, EA; Fisher, MM; Lemay, D, 2014) |
| "She also exhibited precocious puberty and growth hormone deficiency and required treatment for improving final height." | ( Marco, FC; Nso-Roca, AP; Ricote, JM; Ruiz, MJ, 2014) |
| "The most common cause of precocious puberty is idiopathic central precocious puberty (CPP), which is usually treated with monthly injections." | ( Brown, K; Haynes, J; Lanning, D; Maarouf, R; Parrish, D; Poppe, M; Rosati, S, 2015) |
| "To report our experience of treating central precocious puberty (CPP) with a GnRH analogue with respect to the final heights (FH) attained in patients who completed treatment." | ( Borges, Mde F; Cambraia, TC; Ferreira, BP; Franciscon, Pde M; Oliveira, DM; Palhares, HM; Resende, EA, 2015) |
| "We present the case of a girl with precocious puberty treated with triptorelin acetate who developed pseudotumor cerebri after the 4th dose." | ( Gül, Ü; Gümüş, H; Hatipoğlu, N; Kaçar Bayram, A; Kendirci, M; Kurtoğlu, S; Okdemir, D, 2016) |
| "In the precocious puberty girls, the AMH levels based on the GnRH agonist treatment stage were all within the normal reference range." | ( Kim, HR; Lee, KH; Nam, HK; Rhie, YJ, 2017) |
| "Central precocious puberty was diagnosed, and treatment with GnRH analogues was started." | ( Cayirli, H; Ersoy, B; Gunsar, C; Kizilay, D; Temiz, P, 2017) |
| "Children with central precocious puberty (CPP) are treated with gonadotropin-releasing hormone agonists (GnRHa) to suppress puberty." | ( Bacher, P; Dragnic, S; Klein, KO; Soliman, AM, 2018) |
| "A diagnosis of idiopathic central precocious puberty was made and the patient was started on leuprolide depot treatment." | ( Lenet, S; Polychronakos, C, 2019) |
| "Methods Sixty-six female precocious puberty patients were enrolled prospectively for the study at Kangdong Sacred Heart Hospital of Hallym University Medical Center from September 2011 to December 2012 and self-administered questionnaire was completed during the GnRHa treatment initiation period and after 12 months from the first injection." | ( Hwang, IT; Yang, S; Yu, R, 2019) |
| "Treatment of central precocious puberty (CPP) is based on administration of GnRH agonists in order to suppress hypothalamic-pituitary-gonadal axis and thus induce the stabilization or regression of pubertal development." | ( Albertini, R; Bozzola, E; Bozzola, M; Calcaterra, V; De Filippo, G; Messini, B; Monti, CM; Rendina, D; Villani, A, 2021) |
| "A consensus on how to monitor girls with central precocious puberty (CPP) during gonadotropin-releasing hormone agonist (GnRHa) treatment is lacking." | ( Hagstroem, S; Handberg, A; Hvelplund, AH; Leunbach, TL; Schubert, S, 2021) |
| "The PREFER (PREcocious puberty, FERtility) study prospectively analysed fertility, via a series of questionnaires, in women treated during childhood with triptorelin (depot formulation) for CPP." | ( Blumberg, J; Carel, JC; de Mouzon, J; di Nicola, L; Maisonobe, P; Martinerie, L, 2020) |
| "Sixty girls with precocious puberty were randomly divided into a control group (30 cases, 2 cases dropped off) and a treatment group (30 cases, 3 cases dropped off)." | ( Liu, LL; Lü, YW; Sun, HH; Wan, NJ; Zhang, YM, 2023) |
| "Subsequently, progressing precocious puberty was arrested with gonadotrophin-releasing hormone analog therapy." | ( Chen, H; Mo, CY; Zhong, LY, 2023) |